Molecular properties of gp100‐reactive T‐cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells

Authors:

Abstract
To study the contribution of T‐cell receptors (TCR) to resulting T cell responses, we studied three different human αβ TCRs, reactive to the same gp100‐derived peptide presented in the context of HLA‐A*0201. When expressed in primary CD8 T cells, all receptors elicited classic antigen‐induced IFN‐γ responses, which correlated with TCR affinity for peptide‐MHC in the order T4H2>R6C12>SILv44. However, SILv44 elicited superior IL‐17A release. Importantly, in vivo, SILv44‐transgenic T cells mediated superior anti‐tumor responses to 888‐A2+ human melanoma tumor cells upon adoptive transfer into tumor‐challenged mice while maintaining IL‐17 expression. Modeling of the TCR ternary complexes suggested architectural differences between SILv44 and the other complexes, providing a potential structural basis for the observed differences. Overall, the data reveal a more prominent role for the T‐cell receptor in defining host T‐cell physiology than traditionally assumed, while parameters beyond IFN‐γ secretion and TCR affinity ultimately determine the reactivity of tumor‐reactive T cells.
Funding Information
  • National Institute of General Medical Sciences (R35GM118166)
  • National Cancer Institute (R01CA109536, R01CA191317)
  • Indiana Clinical and Translational Sciences Institute (UL1TR001108)
  • LAM Foundation
  • National Eye Institute (PO1CA154778)
  • National Institutes of Health (R01AI29543)
  • Walther Cancer Foundation

This publication has 39 references indexed in Scilit: